Personalised medicine for non-classic cystic fibrosis resulting from rare CFTR mutations

Eur Respir J. 2020 Jul 30;56(1):2000062. doi: 10.1183/13993003.00062-2020. Print 2020 Jul.

Matthew S McCravy¹, Nancy L Quinney², Deborah M Cholon², Susan E Boyles², Timothy J Jensen², Andrei A Aleksandrov^{2

3}, Scott H Donaldson^{1

4}, Peadar G Noone^{1

4

5}, Martina Gentzsch^{6

7

5}

¹ Dept of Medicine, University of North Carolina, Chapel Hill, NC, USA.
² Marsico Lung Institute/Cystic Fibrosis Research Center, University of North Carolina, Chapel Hill, NC, USA.
³ Dept of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC, USA.
⁴ Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina, Chapel Hill, NC, USA.
⁵ M. Gentzsch and P.G. Noone contributed equally to this article as lead authors and supervised the work.
⁶ Marsico Lung Institute/Cystic Fibrosis Research Center, University of North Carolina, Chapel Hill, NC, USA [email protected].
⁷ Dept of Cell Biology and Physiology, University of North Carolina, Chapel Hill, NC, USA.

No abstract available

Publication types